AC Immune(ACIU) Newsfilter·2024-05-28 11:00Core Insights - AC Immune SA is participating in the Jefferies 2024 Global Healthcare Conference on June 5-6, 2024, in New York, with a fireside chat scheduled for June 5 at 3:30 PM (ET) [1] - The company is focused on precision medicine for neurodegenerative diseases, including Alzheimer's and Parkinson's, and has a diversified pipeline with 16 therapeutic and diagnostic programs [3] Company Overview - AC Immune SA is a clinical-stage biopharmaceutical company recognized as a leader in precision prevention for neurodegenerative diseases driven by misfolded proteins [3] - The company has two clinically validated technology platforms, SupraAntigen® and Morphomer®, which support its pipeline [3] - AC Immune has secured strategic partnerships with leading pharmaceutical companies, resulting in over $4.5 billion in potential milestone payments and royalties [3]